Tag: lung cancer
1. Postoperative radiotherapy for pIIIA-N2 non-small cell lung cancer did not improve disease-free survival or overall survival, but did improve locoregional recurrence-free survival.
Evidence Rating Level: 1 (Excellent)
The use of postoperative radiotherapy (PORT) has been correlated with increased survival for non-small cell lung cancer (NSCLC) patients, particularly the pN2 NSCLC...
1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, locally advanced, stage III non-small cell lung cancer.
2. This treatment regimen represents a promising therapy in patients with previously untreated, locally advanced, stage III non-small cell lung cancer, regardless...
1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher objective response rate, compared with chemotherapy alone.
Evidence Rating Level: 1 (Excellent)
Squamous non-small-cell lung cancers (sq-NSCLCs) are often diagnosed at a later stage, leading to poor prognosis and difficult disease...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy.
2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib.
2. Lorlatinib treated patients had improved overall cancer response including greater intracranial response.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Anaplastic lymphoma kinase (ALK) chromosome rearrangement is a target for anti-cancer treatment...
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib.
2. Lorlatinib treated patients had improved overall cancer response including greater intracranial response.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Anaplastic lymphoma kinase (ALK) chromosome rearrangement is a target for anti-cancer treatment...
1. A deep-learning network using chest radiographs and basic demographic information was able to predict lung cancer incidence similar to other high performing models
2. The model also predicted lung cancer deaths with similar accuracy to other high performing models
Evidence Rating Level: 3 (Average)
Study Rundown: Lung cancer screening had been...
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded with the approval of targeted therapies
2. The improved mortality of small cell lung cancer was not driven by treatment advancement but rather a decrease in the incidence
Evidence Rating Level:...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.
2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.
2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...